Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.64 |
| ▸ | LMNA | P02545 | 2/20 | 0.64 |
| ▸ | GAA | P10253 | 1/20 | 0.64 |
| ▸ | HTT | P42858 | 1/20 | 0.60 |
| ▸ | HPGD | P15428 | 4/20 | 0.57 |
| ▸ | MAPT | P10636 | 7/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | TP53 | P04637 | 3/20 | 0.54 |
| ▸ | BCAT2 | O15382 | 5/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 2/20 | 0.49 |
| ▸ | BLM | P54132 | 1/20 | 0.49 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL263943 | 0.79 | KDM4E (1.00) | KDM4ELMNAGAAHTTHPGD | |
| SCHEMBL14635195 | 0.78 | KDM4E (0.62) | KDM4ELMNAGAAHTTHPGD | |
| SCHEMBL4518642 | 0.76 | PIP4K2A (0.66) | KDM4ELMNAGAAHPGDMAPT | |
| SCHEMBL265344 | 0.74 | HPGD (1.00) | KDM4ELMNAGAAHTTHPGD | |
| SCHEMBL262735 | 0.73 | LMNA (0.52) | LMNAHTTHPGDMAPTALDH1A1 | |
| SCHEMBL263739 | 0.70 | BCAT2 (1.00) | KDM4ELMNAGAAHTTHPGD | |
| SCHEMBL4510264 | 0.69 | ALDH1A1 (0.57) | KDM4ELMNAGAAHPGDMAPT | |
| SCHEMBL4520845 | 0.69 | KMT2A (0.78) | KDM4ELMNAHPGDMAPTALDH1A1 | |
| SCHEMBL19119395 | 0.69 | BCAT2 (0.76) | KDM4ELMNAGAAHTTHPGD | |
| SCHEMBL3492352 | 0.69 | PDE5A (0.69) | KDM4EHTTHPGDMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130023546-A1 | THIENOPYRIMIDINE DERIVATIVES | GOTANDA KOTARO (JP) | 2013-01-24 | — | — | US | disclosed |
| US-8293754-B2 | Thienopyrimidine derivatives | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2012-10-23 | — | — | US | disclosed |
| US-20090203703-A1 | Thienopyrimidine Derivatives | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130023546-A1 | THIENOPYRIMIDINE DERIVATIVES | PDE9A, BPHL, THOP1 | KDM4E 2859/4885LMNA 4474/4885GAA 4052/4885 |
| US-20090203703-A1 | Thienopyrimidine Derivatives | PDE9A, BPHL, THOP1 | KDM4E 2859/4885LMNA 4474/4885GAA 4052/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.